Randomized Controlled Trial of Gemcitabine Combined With 125I Brachytherapy
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
For patients with unresectable locally advanced pancreatic cancer, the combined use of
external-beam radiation therapy (EBRT) and systemic chemotherapy of 5-FU has been widely
recognized as the most effective chemoradiotherapy approach.But most patients succumb to
local recurrence and metastasis after treatment, and the prognosis remains poor On the basis
of the development and superiority of the interstitial brachytherapy and the radiosensitizing
effect of gemcitabine, we performed a clinical study to explore the interaction of improved
I-125 brachytherapy and gemcitabine and compare the regimen to the standard gemcitabine
treatment specifically in patients with non-metastatic, unresectable pancreatic cancer.